ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.

Front Immunol · 2020 · PMC7641627 · PMID 33193388

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendp > 0.07so close (0.05 < p ≤ 0.1)

Mice with delayed ERBB2-CAR CIK cell treatment on days +22 and +57 after tumor cell injection experienced significantly improved survival compared to untreated controls ( p < 0.01, Figure 3B ), whereas WT CIK cell-treated mice only showed a trend toward improved survival ( p > 0.07).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.